The purpose of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cancer Functional Imaging Core (CFIC) is to integrate state-of-the-art noninvasive imaging capabilities to advance the translational research mission of SKCCC members. Within the past five, years the Core has significantly expanded to include an Olympus multiphoton microscope for in vivo imaging, a LI-COR Pearl imager, a SuperArgus PET/CT scanner and a Vector SPECT/PET scanner. These are in addition to the existing 9.4T Bruker horizontal bore MR scanner, Kodak and Xenogen optical imaging systems, a Gamma-Medica CT/SPECT and an Argus PET imaging system, and a VisualSonics ultrasound imaging system. The equipment is housed in a 2,400 ft2 small- animal imaging facility in Miller Research Building (MRB), overseen by dedicated technical staff members. These Cancer Functional Imaging Core facilities provide SKCCC members with advanced small-animal imaging capabilities that result in high-impact peer-reviewed publications and research funding. These imaging techniques are translatable into the clinic, providing imaging data in small animals used to develop translational applications in humans. Zaver M. Bhujwalla, Ph.D., is the Director of the Cancer Functional Imaging Core. She is also Program Co- Leader of the SKCCC Cancer Molecular and Functional Imaging Program and the Director of the Johns Hopkins University ICMIC (In Vivo Cellular Molecular Imaging Center) Program. Dr. Bhujwalla directs a newly created Division of Cancer Imaging Research in the Department of Radiology and Radiological Science. Dr. Bhujwalla has an outstanding track record in molecular imaging applications in cancer. The two Associate Directors, Martin G. Pomper, M.D., Ph.D., and Dmitri Artemov, Ph.D., are well-known investigators who played a key role in the establishment of molecular imaging at The Johns Hopkins University (JHU). Dr. Pomper directs the Division of Nuclear Medicine and Molecular Imaging. He is also Co-Leader of the SKCCC Cancer Molecular and Functional Imaging Program and Associate Director of the JHU ICMIC. SKCCC Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-55
Application #
9519873
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
55
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications